Pharmacy Guidance on GLP-1s and Compounded Peptide Therapies

Pharmacy Guidance on GLP-1s and Compounded Peptide Therapies

The explosion of patient interest in GLP-1 receptor agonists has placed pharmacists in a critical advisory role. A recent release from Pharmacy Times provides structured counseling guidance aimed at helping pharmacy professionals navigate the surge in inquiries about both branded and compounded peptide therapies. The document focuses on equipping pharmacists with the factual clarity needed to address patient questions about safety, efficacy, and regulatory status. This article expands on that guidance, adding scientific and clinical context to the key counseling points.

The Rise of GLP-1 Receptor Agonists: Mechanism and Demand

GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, an incretin hormone secreted by intestinal L cells in response to food intake. Under normal physiology, GLP-1 binds to receptors on pancreatic beta cells to stimulate insulin secretion in a glucose-dependent manner, thereby reducing postprandial hyperglycemia. It also suppresses glucagon release, slows gastric emptying, and promotes satiety via central appetite centers in the hypothalamus.

Several GLP-1 receptor agonists have been approved by the U.S. Food and Drug Administration (FDA) for type 2 diabetes and, more recently, for chronic weight management. Semaglutide (marketed as Ozempic for diabetes and Wegovy for obesity), liraglutide (Victoza and Saxenda), and tirzepatide (Mounjaro and Zepbound) are among the most widely prescribed. The landmark STEP clinical trial program for semaglutide demonstrated an average weight loss of approximately 15% after 68 weeks in participants with obesity, while the SURPASS trials for tirzepatide showed even more pronounced metabolic effects. These results have driven unprecedented demand, leading to periodic drug shortages and prompting patients to seek alternative sources.

Pharmacists must explain that GLP-1s are not a one-size-fits-all solution. The medications require careful dosing titration, typically starting at a low dose to mitigate gastrointestinal side effects such as nausea, vomiting, and diarrhea. Some patients also experience more serious adverse events, including acute pancreatitis or a possible increased risk of thyroid C-cell tumors, as indicated by rodent studies. The Pharmacy Times guidance emphasizes that patients should understand these risks before initiating therapy.

Compounded Therapies and Patient Questions

During periods of shortage, compounding pharmacies have stepped in to produce compounded versions of GLP-1 receptor agonists. These are not FDA-approved products but are prepared based on a licensed prescriber’s prescription for an individual patient. According to the guidance, patients frequently ask about the safety, efficacy, and regulatory status of these compounded alternatives.

Pharmacists must be prepared to discuss the fundamental differences between FDA-approved branded medications and compounded preparations. Branded products undergo rigorous preclinical and clinical testing for purity, potency, stability, and sterility. Compounded versions are exempt from that approval pathway but are subject to state pharmacy board regulations and, for facilities that compound in bulk under Section 503B of the Federal Food, Drug, and Cosmetic Act, additional FDA oversight.

However, not all compounding pharmacies operate at the same standard. The Pharmacy Times guidance highlights the importance of understanding both state and federal regulations. Some compounding facilities use active pharmaceutical ingredients (APIs) that may differ from the branded formulation’s manufacturer, and the stability of the final product can vary. For example, GLP-1 peptides are fragile and require specific storage conditions, typically refrigeration at 2–8°C and protection from light. Improper handling can lead to degradation, reduced potency, or contamination. Pharmacists should encourage patients to verify that the compounding pharmacy is licensed and, if possible, accredited by the Pharmacy Compounding Accreditation Board (PCAB) or equivalent bodies.

Counseling Points for Pharmacists

The Pharmacy Times article outlines several core counseling points that pharmacists should communicate to patients. The first is a clear explanation of how GLP-1s work. Many patients mistakenly believe these drugs “burn fat” or directly speed metabolism. Instead, the mechanism involves delayed gastric emptying, enhanced satiety, and improved glycemic control. Pharmacists can use a simple analogy: the drug makes the patient feel fuller faster and for longer after eating, leading to reduced caloric intake.

Second, discussing potential side effects is essential. The most common are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These often resolve with dose titration. More serious but rare effects include acute pancreatitis (severe abdominal pain radiating to the back), gallbladder disease (cholelithiasis or cholecystitis), and retinopathy complications in diabetic patients. Pharmacists should advise patients to seek medical attention if they experience severe or persistent symptoms. The guidance stresses that patients must consult their healthcare provider before starting any new therapy, especially if they are taking other medications for diabetes or weight management.

Third, storage and administration must be addressed. Most branded GLP-1s are injectable pens for subcutaneous administration. Patients need instruction on injection technique: rotating sites (abdomen, thigh, upper arm), using a new needle each time, and not administering if the solution is cloudy or discolored. Compounded versions may come as vials requiring dose measurement, which introduces risk of dosing errors. Pharmacists should demonstrate proper use and encourage patients to follow the specific instructions provided by the prescriber or compounding pharmacy.

Finally, the guidance emphasizes the role of medical supervision. GLP-1 therapy is not intended for standalone use. It works best alongside lifestyle modifications including a reduced-calorie diet and increased physical activity. Regular monitoring of blood glucose, renal function, and pancreatic enzymes may be necessary. For compounded therapies, pharmacists should reinforce that the product is made for a specific patient and should not be shared or used beyond the prescribed duration.

What Patients Want to Know

Patients approaching pharmacists with questions about GLP-1s and compounded versions are often seeking clarity on three main issues: availability, cost, and legitimacy.

Availability is directly tied to the ongoing shortage of branded GLP-1 products. The FDA has listed semaglutide injections on its drug shortage database intermittently since 2022, and manufacturers have ramped up production but have been unable to fully meet demand. Compounded versions fill this gap, but availability depends on the compounding pharmacy’s supply of API and its ability to maintain sterility.

Cost is another driving factor. Branded GLP-1s can cost more than $1,000 per month without insurance, and many insurance plans require prior authorization or step therapy. Compounded versions are typically less expensive because they are not subject to the same research and marketing costs. However, patients should be warned that lower cost does not guarantee equivalency in efficacy or safety. Pharmacists can help patients compare prices and understand what their insurance covers for branded drugs.

Legitimacy is perhaps the most nuanced concern. The guidance notes that patients are trying to differentiate between reputable compounding pharmacies and unregulated sources, including illicit online sellers. Pharmacists should direct patients to check whether the pharmacy is licensed in their state, whether it uses FDA-registered facilities, and whether the product has been tested for identity and potency. Some compounding pharmacies post certificates of analysis for their preparations, which patients can request.

The guidance also mentions that patients are interested in understanding the differences between various peptide-based treatments. For example, semaglutide and tirzepatide are both GLP-1 receptor agonists, but tirzepatide also activates GIP receptors, leading to potentially greater weight loss. Non-GLP-1 peptides like ipamorelin or growth hormone releasing peptides are also circulating in popular culture. Pharmacists must be able to distinguish approved uses from off-label or unsubstantiated claims.

Regulatory and Ethical Considerations

Compounded peptides operate in a complex regulatory gray zone. The FDA generally does not enforce premarket approval for compounded drugs as long as they are prepared in accordance with section 503A of the FD&C Act for individual patients, or under 503B for outsourcing facilities. However, during a shortage of an FDA-approved drug, the agency exercises enforcement discretion and allows compounding from the same API. This discretion does not mean the products are approved or risk-free. Pharmacists must be aware that state boards of pharmacy have additional oversight, and that liability falls on the prescriber and compounder.

The Pharmacy Times guidance underscores the ethical duty of pharmacists to provide accurate, balanced information. They must neither overstate the safety of compounded products nor dismiss their potential value when access to branded medication is limited. The goal is to help patients make informed decisions by presenting the evidence, including the lack of large-scale clinical trials for compounded GLP-1s, the importance of verifying pharmacy credentials, and the necessity of ongoing medical follow-up.

Frequently Asked Questions

Q: Are compounded GLP-1 therapies as safe and effective as the FDA-approved versions?

A: Compounded GLP-1 preparations are not FDA-approved, meaning they have not undergone the same rigorous testing for safety, purity, and efficacy. While they are prepared by licensed pharmacists following state and federal regulations, there is greater variability in potency, sterility, and stability. Research directly comparing compounded to branded GLP-1s is limited. Pharmacists recommend that patients only use compounded products from accredited pharmacies and under the supervision of a healthcare provider.

Q: How can I verify if a compounding pharmacy is reputable?

A: Check if the pharmacy is licensed in your state through the state board of pharmacy website. Look for accreditation from the Pharmacy Compounding Accreditation Board (PCAB) or equivalent. Reputable pharmacies will provide a certificate of analysis for each batch, showing the product’s identity, purity, and strength. Avoid online sellers that do not require a prescription or offer unusually low prices, as these may be counterfeit or adulterated.

Q: What are the most common side effects of GLP-1 receptor agonists?

A: The most frequent side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These often occur during dose escalation and improve over time. More serious but rare side effects include acute pancreatitis, gallbladder disease, and a potential risk of medullary thyroid carcinoma (based on animal studies). Patients should report severe abdominal pain, persistent vomiting, or vision changes to their doctor.

Q: If I cannot afford the branded medication, is a compounded version a reasonable alternative?

A: Compounded versions can be a more affordable option, but they are not a direct substitute. Patients should discuss with their prescriber whether a compounded product is appropriate given their medical history and the availability of other alternatives, such as different branded GLP-1s or generic liraglutide. Always ensure the compounding pharmacy is reputable, and never use a product without a prescription and medical supervision.